|
**Overview**: Anti-Neutrophil Cytoplasmic Antibody IFA Dilutions Panel**Introduction**: The Anti-Neutrophil Cytoplasmic Antibody IFA Dilutions Panel is a diagnostic tool designed to quantify ANCA for vasculitis diagnosis using serum samples. In India, ANCA titers help monitor disease activity in AAV (prevalence ~10-20 per million), with high titers correlating with active disease in granulomatosis with polyangiitis and microscopic polyangiitis. Symptoms include renal failure, pulmonary hemorrhage, sinusitis, or skin lesions. High morbidity from underdiagnosis in rural areas, limited monitoring, and delayed therapy escalation. Per immunology practices aligned with ICMR guidelines, the test employs immunofluorescence dilutions for titer quantification over 1-2 days with high sensitivity/specificity, valuable for assessing disease severity and response. This diagnostic falls under autoimmune screening and targets patients with positive ANCA, addressing accurate titer monitoring to guide immunosuppressive therapy. With morbidity elevated due to underdiagnosis, the test supports public health efforts by enabling precise disease activity assessment, facilitating management, and reducing organ damage. Its serum-based approach ensures reliable detection.**Other Names**: ANCA IFA Dil Pnl.**FDA Status**: FDA approved, CLIA certified for immunology, compliant with 2025 standards.**Historical Milestone**: Developed for titer quantification; in India, used in vasculitis clinics for monitoring.**Purpose**: The test quantifies 3 parameters including c-ANCA titer to guide vasculitis diagnosis, monitor disease activity, inform treatment adjustments.**Test Parameters**: 1. c-ANCA Titer, 2. p-ANCA Titer, 3. Atypical ANCA Titer.**Pretest Condition**: No fasting required; patients should report ongoing vasculitis symptoms or known ANCA positivity.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on vasculitis history, current symptoms, prior treatment, or organ involvement.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated vasculitis including organ failure, benefits of monitoring, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunofluorescence by trained personnel to ensure sterile technique, avoid hemolysis, and interpret titers within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or concurrent infections can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: High titers indicate active disease, necessitating further investigation or treatment escalation. Low/negative results may require follow-up if symptoms persist.**Specialist Consultation**: Rheumatologists or nephrologists should be consulted for case management, treatment planning.**Additional Supporting Tests**: ANCA ELISA or biopsy for confirmation.**Test Limitations**: Titers may not always correlate with activity; comprehensive approach required.**References**: Indian Journal of Rheumatology 2024, Vasculitis Studies India 2023. |
